Summit Midstream Corporation Announces Final Investment Decision on Double E Pipeline Mainline Compression Expansion

NEWS PROVIDED BY

Summit Midstream Corporation

Aug 31, 2026, 07:00 ET

SHARE THIS ARTICLE

HOUSTON, Aug. 31, 2026 /PRNewswire/ -- Summit Midstream Corporation (NYSE: SMC) ("Summit", "SMC" or the "Company") announced today that Double E Pipeline, LLC ("Double E") has concluded a successful open season and reached a final investment decision on its previously announced mainline compression expansion project, supported by a new long-term firm transportation agreement with an investment-grade shipper.

Highlights

Reached a final investment decision on the mainline compression expansion, with an expected in-service date in the fourth quarter of 2028

Executed a new long-term take-or-pay firm transportation agreement with an investment-grade shipper for 200 MMcf/d, bringing total contracted firm capacity on Double E to approximately 2.2 Bcf/d

Converted the $50 million uncommitted accordion at Summit Permian Transmission to committed, bringing total committed financing capacity to $100 million and fully funding Summit's expected Double E capital contributions

Robust future growth opportunities associated with data center developments in Texas and New Mexico and connectivity with additional egress pipelines

Management Commentary

Heath Deneke, President, Chief Executive Officer and Chairman, commented, "Today's announcement is a significant milestone for Summit and Double E and further demonstrates the importance of the pipeline to producers and processors in the Delaware Basin. Double E provides reliable gas transmission service with access to multiple downstream markets, and we continue to expand that connectivity as the basin grows. The strong shipper interest we have seen through the open season reinforces the value of that position and our confidence in the long-term growth opportunity for Double E.

"The open season resulted in 550 MMcf/d of new long-term take-or-pay commitments which underpinned the final investment decision to move forward with the compression expansion and we continue to advance discussions with multiple shippers to subscribe the remaining 450 MMcf/d of incremental forward haul capacity. With these newly signed contracts, we expect to invest approximately $100 million, net to Summit's 70% interest, to install the mainline compression station, incremental plant connections and related infrastructure, all of which will be funded entirely with the previously announced term loan at Summit Permian Transmission and the now-committed $50 million accordion. We continue to see tremendous production growth surrounding our Delaware Basin operating footprint and fully expect to enter into long-term contracts for the remaining expansion capacity in the coming months. When the project is fully subscribed, we expect our Permian Segment Adjusted EBITDA to grow from approximately $37 million in 2026 to over $100 million by 2030."

"As we look into the future for the Double E Pipeline beyond filling the mainline compression expansion capacity to Waha, we are very excited about a new phase of demand-pull growth opportunities that are emerging from data center development in Texas and New Mexico as well as additional egress pipelines that are hungry for enhanced access to Permian gas supply. With our connectivity to numerous gas processing facilities in the basin and the Waha Hub, we are incredibly well positioned to attract those markets to the Double E Pipeline and leverage the bi-directional capability of the system to nearly double the outlook for the business in the years ahead."

Double E Mainline Compression Expansion

The expansion project consists of the installation of a bi-directional mainline compressor station on the Double E system, which will increase the pipeline's forward haul capacity to Waha by approximately 900 MMcf/d. The compression project along with new plant connections and related infrastructure is expected to cost approximately $100 million net to Summit's 70% interest and is expected to be placed in service by the fourth quarter of 2028.

The Double E joint venture has already placed a purchase order for the long-lead gas turbine compression units required for the project, securing manufacturing slots necessary to support the targeted in-service date. The project remains subject to FERC and other customary regulatory approvals.

With the new 200 MMcf/d agreement, Double E has secured approximately 550 MMcf/d of binding long-term take-or-pay commitments through the compression expansion open season. Total contracted firm capacity on the pipeline is now approximately 2.2 Bcf/d, held by a diversified group of primarily investment-grade shippers. Double E continues to advance discussions with additional prospective shippers regarding remaining capacity on the expansion.

Summit Permian Transmission Financing

In connection with the final investment decision, Summit Permian Transmission converted the previously uncommitted $50 million accordion under its existing $440 million senior secured term facility maturing in March 2031 into a committed facility. Combined with the $50 million committed delayed draw term facility established at closing in March 2026, Summit expects to have sufficient commitments to fund all of its expected capital contributions to Double E over the next several years. The Summit Permian Transmission term facility remains non-recourse to SMC.

About Double E Pipeline, LLC

Double E is a 135-mile FERC-regulated interstate natural gas transmission pipeline that commenced operations in November 2021 and provides transportation service from receipt points in the Delaware Basin to various delivery points in and around the Waha Hub in Texas.

Double E is owned by subsidiaries of Summit Midstream Corporation (NYSE: SMC) and ExxonMobil (NYSE: XOM) with an ownership interest of 70% and 30%, respectively. Summit Midstream Permian II, LLC is the operator of Double E.

About Summit Midstream Corporation

SMC is a value-driven corporation focused on developing, owning and operating midstream energy infrastructure assets that are strategically located in the core producing areas of unconventional resource basins, primarily shale formations, in the continental United States. SMC provides natural gas, crude oil and produced water gathering, processing and transportation services pursuant to primarily long-term, fee-based agreements with customers and counterparties in five unconventional resource basins: (i) the Williston Basin, which includes the Bakken and Three Forks shale formations in North Dakota; (ii) the Denver-Julesburg Basin, which includes the Niobrara and Codell shale formations in Colorado and Wyoming; (iii) the Fort Worth Basin, which includes the Barnett Shale formation in Texas; (iv) the Arkoma Basin, which includes the Woodford and Caney shale formations in Oklahoma; and (v) the Piceance Basin, which includes the Mesaverde formation as well as the Mancos and Niobrara shale formations in Colorado. SMC has an equity method investment in Double E Pipeline, LLC, which provides interstate natural gas transportation service from multiple receipt points in the Delaware Basin to various delivery points in and around the Waha Hub in Texas. SMC is headquartered in Houston, Texas.

Forward-Looking Statements

This press release includes certain statements concerning expectations for the future that are forward-looking within the meaning of the federal securities laws. Forward-looking statements include, without limitation, any statement that may project, indicate or imply future results, events, performance or achievements and may contain the words "expect," "intend," "plan," "anticipate," "estimate," "believe," "will be," "will continue," "will likely result," and similar expressions, or future conditional verbs such as "may," "will," "should," "would" and "could." In addition, any statement concerning future financial performance (including future revenues, earnings or growth rates), payment of dividends on any series of stock, ongoing business strategies and possible actions taken by SMC or its subsidiaries are also forward-looking statements. Forward-looking statements also contain known and unknown risks and uncertainties (many of which are difficult to predict and beyond management's control) that may cause SMC's actual results in future periods to differ materially from anticipated or projected results. An extensive list of specific material risks and uncertainties affecting SMC is contained in its 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 16, 2026, as amended and updated from time to time. Any forward-looking statements in this press release are made as of the date of this press release and SMC undertakes no obligation to update or revise any forward-looking statements to reflect new information or events.

SOURCE Summit Midstream Corporation

21%

more press release views with 

Request a Demo

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

NEWS PROVIDED BY

Eli Lilly and Company

Aug 31, 2026, 07:00 ET

SHARE THIS ARTICLE

 At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials

Systemic inflammation and metabolic outcomes continued to improve or were sustained at one year with Taltz and Zepbound compared to Taltz alone in pre-specified, exploratory endpoints

Data from first-of-their-kind studies contribute to the understanding of immunometabolic health

INDIANAPOLIS, Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced 52-week results from TOGETHER-PsO and TOGETHER-PsA, two novel open-label Phase 3b clinical trials evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), respectively, and obesity or overweight with at least one additional weight-related comorbid condition. At the previously reported Week 36 primary endpoint, Taltz and Zepbound showed statistically superior improvements in disease activity and metabolic outcomes compared to Taltz alone in both trials. New data show these improvements were maintained or further improved through Week 52, with no new safety concerns identified.

"The primary results from these first-of-their-kind studies were already remarkable, showing that Taltz and Zepbound used together improved outcomes for patients with psoriatic disease and obesity. What's especially exciting now is seeing those improvements further deepened or sustained at one year, across disease activity, inflammation and metabolic outcomes," said Mark Genovese, M.D., senior vice president of Lilly Immunology development. "People living with the cumulative burden of psoriatic disease and obesity are too often treated with separate, disconnected approaches. These data showing durable results across multiple measures support a comprehensive approach that can potentially address immunometabolic health for patients living with these chronic diseases."

Psoriasis and psoriatic arthritis are immune-mediated diseases that are often linked with metabolic dysfunction, including obesity.1,2 In the U.S., approximately 61% of people with psoriasis and 65% of people with psoriatic arthritis also have obesity or overweight with at least one weight-related comorbidity,1,2 which is often associated with poorer treatment outcomes.3-5 At baseline, the mean body mass index (BMI) of participants was 39.2 in TOGETHER-PsO and 37.6 in TOGETHER-PsA.

"Psoriatic disease is often accompanied by obesity or overweight, which can make treatment goals related to the skin and joints harder to reach," said Joseph F. Merola, M.D. MMSc, a Dermatologist, Rheumatologist, President of the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN), co-president of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), and President of the Rheumatology-Dermatology Society. "In psoriatic arthritis, the greater improvements in disease activity seen with Taltz and Zepbound in the first month, before clinically meaningful weight loss occurred, continued through one year. In psoriasis, the durability of complete skin clearance at one year represents real, lasting progress for patients. Paired with continued metabolic improvements, these findings show what may be possible when treating psoriatic disease and obesity concurrently."

At Week 52, the following were observed:*

Primary outcome: The primary multi-component outcome continued to improve through Week 52 in each trial.

In TOGETHER-PsO, the primary outcome was Psoriasis Area Severity Index (PASI) 100 plus at least 10% weight loss (achieved by 30.6% of patients with Taltz plus Zepbound at Week 52 vs. 4.4% for Taltz alone).

In TOGETHER-PsA, the primary outcome was an at least 50% reduction in PsA disease activity based on American College of Rheumatology 50 (ACR50) plus at least 10% weight loss (achieved by 39.2% of patients with Taltz and Zepbound at Week 52 vs. 1.7% for monotherapy).

PsO disease activity key secondary outcome: In TOGETHER-PsO, the percentage of patients receiving Taltz and Zepbound who achieved the highest bar of complete skin clearance (PASI 100) was maintained (40.5% at Week 52 vs. 29.1% for Taltz monotherapy).

PsA disease activity key secondary outcome: In TOGETHER-PsA, the proportion of patients achieving ACR50 with Taltz and Zepbound further increased (43.7% at Week 52 vs.15.7% for Taltz monotherapy). This builds on the ACR50 improvements with Taltz and Zepbound compared to Taltz alone seen as early as Week 4, before clinically meaningful weight loss was observed.

Systemic inflammation: Treatment with Taltz and Zepbound also led to deeper improvements in systemic inflammation over time in both trials, as measured by high-sensitivity C-reactive protein (hsCRP).

Metabolic outcomes: Improvements in BMI, blood pressure, glucose, HbA1c, triglycerides, and total cholesterol with Taltz and Zepbound compared to Taltz monotherapy were sustained or further improved.

*Week 52 analyses are pre-specified, exploratory objectives without multiplicity control. Comparisons between timepoints are descriptive and not tested or controlled for multiplicity.

Adverse events in participants treated with Taltz and Zepbound together were generally mild to moderate, and the types of adverse events were consistent with the known safety profile of each medicine. In the concomitant treatment arm in both trials, the adverse events reported in ≥5% of participants were nausea, diarrhea, constipation, injection site reactions, vomiting, dizziness and headache.

Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. Taltz is the only biologic with data supporting a potential comprehensive treatment approach alongside an incretin therapy for people with psoriasis or psoriatic arthritis who also have obesity or overweight. Zepbound is the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity management medication.

Detailed 52-week results from TOGETHER-PsO and TOGETHER-PsA will be presented at future medical meetings and published in peer-reviewed journals.

About the TOGETHER-PsO and TOGETHER-PsA Trials

TOGETHER-PsO (NCT06588283) and TOGETHER-PsA (NCT06588296) are 52-week Phase 3b, randomized, multicenter, assessor-blinded, open-label studies assessing the efficacy and safety of concomitant administration of Taltz and Zepbound compared with Taltz alone in adults with psoriatic disease and obesity or overweight with at least one additional weight-related comorbid condition. TOGETHER-PsO enrolled 274 adults with moderate-to-severe plaque psoriasis, and TOGETHER-PsA enrolled 271 adults with active psoriatic arthritis. Participants were randomized 1:1 to receive either Taltz alone or concomitantly with Zepbound, both administered subcutaneously, and received counseling on a reduced-calorie diet and increased physical activity. The primary objectives at Week 36 are the proportion of participants achieving both PASI 100 and ≥10% weight reduction in TOGETHER-PsO and both ACR50 and ≥10% weight reduction in TOGETHER-PsA. Participants were required to have a BMI ≥30 kg/m², or ≥27 to 30 kg/m² with at least one weight-related comorbidity.

About Taltz (ixekizumab)6

Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines. Taltz is approved to treat adults with active psoriatic arthritis and adults and children 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Additionally, Taltz is approved for adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

About Zepbound (tirzepatide) injection7

Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity.

TALTZ INDICATIONS AND SAFETY SUMMARY

Taltz® (tȯl-ts) is an injectable medicine used to treat:

People 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

Adults with active psoriatic arthritis.

Adults with active ankylosing spondylitis.

Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

It is not known if Taltz is safe and effective in children for conditions other than plaque psoriasis or in children under 6 years of age.

Warnings - Taltz affects the immune system. It may increase your risk of infections, some people have had serious infections, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections. Do not use Taltz if you have any symptoms of infection, unless your doctor tells you to. If you have a symptom after starting Taltz, call your doctor right away.

Your doctor should check you for TB before you start Taltz, and watch you closely for signs of TB during and after treatment with Taltz. If you have TB, or had it in the past, your doctor may treat you for it before you start Taltz.

Do not use Taltz if you have had a serious allergic reaction to ixekizumab or any other ingredient in Taltz, such as: swelling of your eyelids, lips, mouth, tongue or throat, trouble breathing, feeling faint, throat or chest tightness, or skin rash. Get emergency help right away if you have any of these reactions. See the Medication Guide that comes with Taltz for a list of ingredients.

Severe skin reactions that look like eczema can happen during treatment with Taltz from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with Taltz if you develop severe skin reactions. Tell your doctor if you have any of the following: redness or rash, itching, patches, your skin is dry or feels like leather, blisters or abrasions that ooze or become crusty, small bumps or plaques with scale or crusting.

Crohn's disease or ulcerative colitis (inflammatory bowel disease) can start or get worse with Taltz use. Tell your doctor if you have any of these symptoms or if they get worse: stomach pain, diarrhea, and weight loss.

You should not get live vaccines while taking Taltz. You should get the vaccines you need before you start Taltz.

Common side effects

The most common side effects of Taltz include:

Injection site reactions

Nausea

Upper respiratory infections

Fungal skin infections

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before you use Taltz, review these questions with your doctor:

Are you being treated for an infection?

Do you have an infection that does not go away or keeps coming back?

Do you have TB or have you been in close contact with someone with TB?

Do you have possible symptoms of an infection such as fever, cough, sores, diarrhea, or other symptoms? Ask your doctor about other possible symptoms.

Do you have Crohn's disease or ulcerative colitis?

Tell your doctor if:

You need any vaccines or have had one recently.

You take prescription or over-the-counter medicines, vitamins, or herbal supplements.

You are pregnant or planning to become pregnant. It is not known if Taltz can harm an unborn baby.

Pregnancy Exposure Registry: There is a pregnancy registry to collect information about women who are exposed to Taltz during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking Taltz, you are encouraged to enroll in the pregnancy registry by calling 1-800-284-1695 or by visiting online at http://www.pregnancyregistry.lilly.com.

You are breastfeeding or planning to breastfeed. It is not known if Taltz passes into breastmilk.

How to take

See the instructions for use that come with Taltz. There you will find information about how to store, prepare, and inject Taltz. Adults may self-inject after receiving training from a healthcare provider.

For children 6 to 17 years of age:

If your child's healthcare provider decides that you may give Taltz injections at home, you should receive training on the right way to prepare and inject Taltz. Do not try to give Taltz to your child until you have been shown how to inject Taltz. Children should not inject themselves with Taltz. You or an adult caregiver should prepare and give Taltz injections to your child.

Learn more

Taltz is a prescription medicine available as a 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection. For more information, call 1-800-545-5979 or go to taltz.lilly.com.

This summary provides basic information about Taltz but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Taltz and how to take it. Your doctor is the best person to help you decide if Taltz is right for you.

IX CON BS 20AUG2024

ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. 

moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Before using Zepbound 

Your healthcare provider should show you how to use Zepbound before you use it for the first time. 

Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. 

If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

Review these questions with your healthcare provider: 

❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ Do you take diabetes medicines, such as insulin or sulfonylureas?

❑ Do you have a history of diabetic retinopathy?

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979).

How to take 

Read the Instructions for Use that come with Zepbound.

Use Zepbound exactly as your healthcare provider says.

Use Zepbound with a reduced-calorie diet and increased physical activity.

Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or 

have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously).

Use Zepbound 1 time each week, at any time of the day. 

Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.

If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more

Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) [or go to www.zepbound.lilly.com].

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 25FEB2026

Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names 

All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for moderate to severe plaque psoriasis and active psoriatic arthritis and Zepbound (tirzepatide) as a treatment for adults with obesity or overweight, and potential comprehensive treatment strategies for patients with psoriatic disease and obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

References

1 Armstrong et al, Addressing the Obesity-Psoriasis Connection: Prevalence, Incidence, and Comorbidity Insights from a Large US Population of 19.9 Million (2018-2024). Presented at Maui Derm, 2026.

2 Estimated from a large real-world population of care-seeking adults in the US in 2024, Truveta (data on file). Comorbidities include atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, obstructive sleep apnea (OSA).

3 Enos, Clinton W. et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, Volume 86, Issue 1, 68 - 76.

4 Proft F, et al. Nat Rev Rheumatol. 2026 Feb;22(2):132-144.

5 di Minno MN, et al. Arthritis Care Res (Hoboken). 2013;65(1):141-147. 

6 Taltz. Prescribing Information. Lilly USA, LLC.

7 Zepbound. Prescribing Information. Lilly USA, LLC.

Refer to:

Kathleen Ritchie; Kathleen.ritchie@lilly.com (Lilly media)

Michael Czapar; czapar_michael_c@lilly.com (Investors)

SOURCE Eli Lilly and Company

21%

more press release views with 

Request a Demo

Perpetua Resources Provides Construction Update on the Stibnite Gold Project and Exploration Activities

NEWS PROVIDED BY

Perpetua Resources Corp.

Aug 31, 2026, 06:59 ET

SHARE THIS ARTICLE

Momentum Builds as Early Works and Critical Path Construction Continues

BOISE, Idaho, Aug. 31, 2026 /PRNewswire/ -- Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources," "Perpetua," or the "Company") today provided an update on critical path construction progress at its Stibnite Gold Project (the "Project") in central Idaho. With federal approvals secured in 2025 and early works and critical path construction activities underway, the Company is pleased to provide updates to shareholders and communities with a clear view of activity on the ground.

Autoclave Fabrication

Permanent Worker Housing Staging Area

Temporary Housing Facility

Permanent Worker Housing Site Preparation

Site Preparation

Burntlog Route Construction

Administrative Pad Preparation

Drilling Team

Exploration Drilling

Core Logging

INL Ribbon Cutting - Left to right: Perpetua CEO Jon Cherry, INL Director John Wagner, Idaho Lt. Governor Scott Bedke, Bob Fox (INL), Idaho Congressman Mike Simpson, Idaho Governor Brad Little, Daniel Flynn (US Army)

New Yellow Pine Community Outpost

"We continue to see tangible progress at Stibnite," said Jon Cherry, President and CEO of Perpetua Resources. "From the arrival of new infrastructure on site and advancements in equipment fabrication to exciting drilling results, this update demonstrates the momentum, focus, and disciplined execution our team is bringing to the Project."

Recent Highlights:

Stibnite Autoclave Fabrication Underway

After submitting purchase orders earlier this year, essential components of the Stibnite Gold Project's dual autoclaves are being fabricated at a custom facility in Europe. The curved plates depicted here are rolled to meet exact standards to fit the autoclave vessel's specified radius before being welded together.

These long-lead equipment items represent key components of the Stibnite processing facility to optimize gold extraction.

Worker Housing Takes Shape

Temporary workforce housing is in place, and Perpetua is now advancing the permanent Worker Housing Facility for the long-term accommodation of the Project's construction and operations workforce. Designed to be self-contained and support year-round activity in a remote environment, the modular units will form the core of the site's workforce lodging throughout the Project life.

As of August 24, 2026, approximately half of the ATCO-supplied units have been delivered to Stibnite. The remaining units are staged 75 miles away in Cascade, and deliveries occur nearly every day. The permanent facility location at Stibnite is ready for installation as grading has been completed and utilities are installed.

Additional On-Site Preparation

Key infrastructure construction continues at the Stibnite Gold Project, including the Administrative Pad area on-site and the Burntlog Route. The initial build-out of the Administrative Pad is underway, which will include a variety of administrative infrastructure, emergency services, and other support facilities. The U.S. Forest Service officially identified the Burntlog Route as the "preferred alternative" and "environmentally preferred alternative" under NEPA. Once the Burntlog Route is completed, it will be the main access route to the Stibnite Gold Project.

Drilling Intensifies with 4 Rigs

With significant mineralization identified in the Company's winter drill program (as noted in the August 6 press release), staff continue to drill prospective targets. Exploration drilling is currently underway with 4 rigs and approximately 5,800 meters of the new 10,000-meter drill program completed to date.

Rigs are spread across various targets, including:

Clark Tunnel Fault Zone (CTFZ): Located within or adjacent to the southeastern limits of the Yellow Pine pit, the CTFZ returned near-surface, high-grade gold intercepts from recent drilling, including 6.4 meters of 16.2 g/t gold & 1.7% antimony from surface and 15.0 meters of 6.3 g/t gold & 0.8% antimony from an 11-meter depth. As these intercepts demonstrate mineralization that is near-surface, within the permitted pit footprint, and at grades that are multiples of reserve grade, Perpetua has elected to continue testing the CTFZ as part of its 10,000-meter 2026 drill program.

In addition to high-grade gold, Perpetua also made a new gold-tungsten discovery of 21.3 meters of 3.2 g/t gold & 0.9% tungsten from a 24-meter depth. Additional occurrences of scheelite, a tungsten-bearing mineral, have been observed in ongoing drilling in the CTFZ.

Huckleberry Fault Zone (HFZ): Lying immediately adjacent to the Yellow Pine reserve pit limits, widely spaced drilling and surface sampling at the HFZ returned broad intervals of gold mineralization, including 69.6 meters of 0.8 g/t gold, akin to the nearby West End reserve pit.

Hangar Flats: Drilling continues to focus on high-grade gold, antimony and tungsten targets at Hangar Flats. Initial drilling tested near-surface targets in the Hangar Flats extensions, including 3.0 meters grading 14.5 g/t gold. Deeper drilling beneath the reserve pit returned high-grade antimony and tungsten intercepts, including 22.9 meters of 3.2% antimony & 1.2% tungsten, 9.8 meters of 8.3% antimony & 4.6% tungsten, and 3.4 meters of 10.6% antimony & 1.5% tungsten. Any tungsten development would require separate environmental review and permitting outside the current Project's scope.

Perpetua, U.S. Army & Idaho National Laboratory Open Antimony Processing Plant

Perpetua Resources, the U.S. Army, and Idaho National Laboratory ("INL") held a ribbon-cutting on July 29, 2026, for a modular mineral processing plant at INL in Idaho Falls, attended by Idaho's Governor, Lieutenant Governor, and Idaho Congressman Mike Simpson.

The plant will initially process antimony samples from Perpetua's Stibnite Gold Project into antimony trisulfide for military use, aiming to rebuild a domestic "ground-to-round" supply chain after China cut off U.S. access to this material in 2021. Antimony trisulfide continues to play an important role in ammunition manufacturing and other military applications. It also plays an integral role in batteries, solar glass, and flame retardants needed by domestic manufacturers. The pilot plant project stems from a multi-year partnership between Perpetua and the U.S. Army's Defense Ordnance Technology Consortium. Since 2022, Perpetua has been awarded over $87 million from the U.S. Department of War and the U.S. Army, including more than $59 million in Defense Production Act funds and a recent $4.7 million award that brought total Army funding under the Ordnance Technology Initiative Agreement (OTIA) to $27 million.

Stibnite holds the only identified antimony reserve in the U.S. and historically supplied over 90% of the antimony and over 50% of the tungsten used by the U.S. government during WWII1. The Stibnite Gold Project received final federal approval in 2025 allowing construction to proceed and is now in early-works and critical path construction, positioning it to supply both antimony and gold while supporting national security and Idaho's economy.

_____________________________

1 "Stibnite Historic District," National Register of Historic Places Nomination Form, NPS Ref. No. 87001186 (listed July 19, 1987).

New Yellow Pine Community Outpost

On Thursday, July 16, Perpetua Resources proudly celebrated the grand opening of The Outpost, a new community resource and visitor information center located in Yellow Pine, Idaho. The event brought together employees, community members, local partners, and visitors to mark an exciting milestone for both the Company and the community.

The Outpost was created to serve as a welcoming space where residents, visitors, recreationists, and anyone interested in the area can learn more about the Stibnite Gold Project. Visitors can view educational displays, ask questions, and receive the latest Project updates in a space designed to foster open dialogue and meaningful engagement with the community.

Litigation Update

On August 18, 2026, the U.S. District Court of Idaho issued a comprehensive ruling affirming the U.S. Forest Service's and other federal agencies' approval of the Stibnite Gold Project. The Court upheld the federal approvals for the Project, rejecting the plaintiffs' challenges that the agency decisions violated the National Environmental Policy Act, the General Mining Law, and the National Forest Management Act, among other federal laws.

The Court further upheld the substance of the federal agencies' decisions under the Endangered Species Act (ESA), including that the Project would not jeopardize any endangered species. On a narrow, discrete issue, the Court remanded back to the U.S. Fish and Wildlife Service (FWS) the agency's Incidental Take Statements, which implement some of the ESA requirements for the Project. The Court instructed FWS to clarify monitoring and reporting measures contained in the existing agency record. The Court's remand does not require reconsideration of the FWS's no-jeopardy findings. Plaintiffs have filed an appeal of the District Court's decision. However, based on the District Court ruling and its earlier denial of the plaintiffs' motion for preliminary injunction, Perpetua continues to move forward with various critical path construction activities.

Website: www.perpetuaresources.com

About Perpetua Resources and the Stibnite Gold Project

Perpetua Resources Corp., through its wholly owned subsidiaries, is focused on the exploration, site restoration and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho. The Stibnite Gold Project is one of the highest-grade, open-pit gold deposits in the United States and holds the only identified domestic reserve of the critical mineral antimony, which is essential to the defense, energy and manufacturing sectors. The Project is designed to apply a modern, responsible mining approach to restore a historic mine site and provide uplift to water quality, improve fish habitat access, and invest in river restoration while supporting local economic development in rural Idaho.

FORWARD-LOOKING INFORMATION

Information and statements contained in this news release that are not historical facts are "forward-looking information" or "forward-looking statements" (collectively, "Forward-Looking Information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. We use words such as "may," "would," "could," "should," "will," "expect," "anticipate," "believe," "intend," "plan," "potential," "estimate," and similar expressions suggesting future outcomes or events to identify forward-looking statements or forward-looking information. Forward-Looking Information includes, but is not limited to, information concerning the business of Perpetua Resources Corp. (the "Company") and the Stibnite Gold Project (the "Project"), including but not limited to the timing and results of construction and early works activities; the design, fabrication, delivery and commissioning of project equipment and infrastructure, including the autoclave; the expected outcomes and benefits of the Project; ongoing funding and anticipated liquidity; the anticipated economic, environmental and other benefits of the Project; ongoing and planned exploration activities; the interpretation of drill results; the potential to supplement or expand existing mine plans; and the potential for future permitting or regulatory approvals related to areas outside the currently permitted Project scope.

In preparing the Forward-Looking Information in this news release, the Company has applied several material assumptions, including, but not limited to, assumptions regarding the interpretation of drill results, the geology, grade, and continuity of mineralization, that current exploration, development, environmental, and other objectives concerning the Project can be achieved, that permitting, construction, or operations costs will not materially increase, and that the Company will continue to satisfy the requirements of applicable permits and governmental approvals, and that the pending appeal and any related future proceedings will not result in the loss of any material permits, a material delay to the Project schedule, or a material increase to Project costs.

Forward-Looking Information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the Forward-Looking Information. Such risks and uncertainties include, among other things, that exploration results may not support the conversion of mineralization into resources or reserves, that additional environmental review or permitting may be required for activities outside the currently permitted Project scope, that development, construction, operations, or permitting costs may increase, and that permitting or other approvals may be delayed as a result of legal challenges, including the limited remand to the U.S. Fish and Wildlife Service, the pending appeal in the ongoing lawsuit challenging the Project and any related proceedings. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. For further information on these and other risks and uncertainties that may affect the Company's business and liquidity, see the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, which are available at www.sec.gov, and with the Canadian securities regulators, which are available at www.sedarplus.ca. Except as required by law, the Company expressly disclaims any obligation to update the Forward-Looking Information herein.

Cautionary Statement Regarding Technical Information

Except for the exploration results presented herein, the technical and reserves information in respect of the Stibnite Gold Project in this news release is based upon information contained in the technical report titled "Stibnite Gold Project, S-K 1300 Technical Report Summary, Valley County, Idaho, USA," dated as of December 31, 2025 (the "TRS"), developed for the Stibnite Gold Project in accordance with S-K 1300 and published on March 31, 2026. Such information is as of December 31, 2025, and is subject to the assumptions, exclusions and qualifications set forth in the TRS. For additional information regarding the TRS, investors are encouraged to refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026. For additional information regarding the exploration results referenced herein, investors are encouraged to refer to the Company's news release dated August 6, 2026.

There can be no assurance that exploration activities will result in the discovery of additional resources or reserves, and isolated exploration results may not be indicative of the occurrence of a mineral deposit. Such results do not provide assurance that further work will establish sufficient grade, continuity, metallurgical characteristics and economic potential to be classed as a category of mineral resource. Exploration results are inherently uncertain and subject to numerous risks and uncertainties, including geological factors, market conditions, and regulatory changes. Furthermore, development of any additional resources and reserves discovered would be subject to any applicable NEPA and permitting requirements.

SOURCE Perpetua Resources Corp.

21%

more press release views with 

Request a Demo

Transformer Monitoring Market worth $4.98 billion by 2031 | MarketsandMarkets™

NEWS PROVIDED BY

MarketsandMarkets

Aug 31, 2026, 06:59 ET

SHARE THIS ARTICLE

DELRAY BEACH, Fla., Aug. 31, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global Transformer Monitoring Market size is projected to grow from USD 3.11 billion in 2026 to USD 4.98 billion by 2031 at a compound annual growth rate (CAGR) of 9.9% during the forecast period.

Browse 150 market data Tables and 60 Figures spread through 250 Pages and in-depth TOC on "Transformer Monitoring Market – Global Forecast to 2031"

The global market is experiencing continued growth as power companies, industrial facilities, and other power users are concentrating more on the reliability of transformers, the health of assets, and the stability of power supply. Transformer monitoring systems are increasingly used to assess operating parameters, detect developing faults, and improve the operation of transformer-related technologies. The need to manage older transformers, enhance asset efficiency, and boost the reliability of power systems has driven the adoption of this technology across transmission, distribution, generation, and industrial processes. Additionally, the rise of alternative energy sources and the growing variability in electricity consumption have created a demand for greater visibility into transformer operating conditions.

The market is also influenced by advancements in online monitoring, IoT-connected sensors, dissolved gas analysis, partial discharge detection, data analytics, and cloud and edge technologies. These monitoring systems integrate various transformer parameters, including temperature, loading, oil quality, dissolved gases, moisture, bushings, and partial discharge, to effectively evaluate transformer conditions. Continuous monitoring enables remote diagnostics, automatic alerts, fleet-level analysis, and condition-based maintenance. Furthermore, integration with digital asset management systems enhances the accessibility and usability of transformer data. Recent developments in sensor connectivity and analytics are also helping to upgrade older transformer fleets through retrofits and newly installed monitoring systems.

Transformer Monitoring Market Size & Forecast:

Market Size Available for Years: 2022–2031

2025 Market Size: USD 2.84 billion

2031 Projected Market Size: USD 4.98 billion

CAGR (2026–2031): 9.9%

Transformer Monitoring Market Trends & Insights:

By region, the Asia Pacific Transformer Monitoring Market is expected to register a CAGR of 10.8% between 2026 and 2031.

By component, the software segment is likely to exhibit a growth rate of 10.8% during the forecast period.

By type, the oil-immersed segment is anticipated to register a 10.1% CAGR from 2026 to 2031.

By application, the power transformers segment is expected to grow at a significant rate during the forecast period.

By service, the dissolved gas analysis segment is likely to exhibit the highest growth during the forecast period

By voltage rating, the above 230 kV segment is projected to hold a dominant position in the market during the forecast period.

By installation, the new segment is expected to register the highest CAGR during the forecast period.

By end user, the power utilities segment is anticipated to record the highest growth rate from 2026 to 2031.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197443553

Oil-immersed segment to record the highest CAGR between 2026 and 2031.

Based on type, the oil-immersed segment is anticipated to exhibit the highest growth rate in the Transformer Monitoring Market during the forecast period. The use of oil-immersed transformers is expected to increase in transmission and distribution networks in industries as well as substation facilities, especially in high-capacity and high-voltage applications. Transformers utilize insulating oil for cooling purposes and dielectric insulation. This makes it necessary to monitor the state of the oil, the dissolved gas, and the temperature, among other operating parameters. With the expansion of the electricity supply networks and the increasing application of oil-immersed transformers in high voltage systems, their efficacy depends on maintaining effective monitoring.

Hardware segment to capture the largest share of the Transformer Monitoring Market in 2026.

Based on component, the hardware component segment is expected to hold the largest market share in 2026, driven by rising investments in grid modernization, transformer asset health, and real-time condition monitoring. Utilities are increasingly deploying sensors, monitoring devices, communication gateways, and data acquisition systems to capture critical parameters such as dissolved gases, temperature, moisture, vibration, bushing condition, and partial discharge. Aging transformer fleets and growing emphasis on predictive maintenance and asset life extension are further accelerating hardware adoption. In addition, the integration of IoT-enabled monitoring infrastructure with digital substations is increasing demand for connected field devices. Expanding renewable energy integration and grid complexity are also strengthening the need for continuous, high-accuracy transformer monitoring hardware.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197443553

Asia Pacific to be the fastest-growing in the Transformer Monitoring Market from 2026 to 2031.

Based on region, Asia Pacific is expected to record the highest growth rate during the forecast period due to rapid urbanization, industrial growth, escalating demand for electricity, and development of new transmission and distribution infrastructure. In addition, the growth of renewable energy capacity is increasing the importance of reliable transformers, especially in the changing power grid environment due to variable generation of electricity. China, India, Japan, South Korea, and countries in Southeast Asia are also investing in grid modernization and digitalization, which promotes the use of modern methods of monitoring, sensors, diagnostic techniques, and asset management systems.

Top Companies in Transformer Monitoring Industry:

The Transformer Monitoring Industry include GE Vernova (US), Schneider Electric (France), Siemens (Germany), Vaisala (Finland), Eaton (Ireland), Mistras Group (US), Vaisala (Finland), Reinhausen GmbH (Germany), Hitachi Energy Ltd. (Switzerland), Qualitrol Company LLC. (US), and Doble Engineering Company (US). These companies are strengthening their market positions through transformer monitoring portfolio expansion, energy-efficiency improvements, product innovations, geographic expansions, strategic acquisitions, and investments in power utilities, industrial, commercial/ residential, and data center applications.

For more information, Inquire Now!

Related Reports:

Transformer Market

Instrument Transformers Market

Electrical Bushings Market

Smart Transformers Market

Get access to the latest updates on Transformer Monitoring Companies and Transformer Monitoring Industry

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

SOURCE MarketsandMarkets

21%

more press release views with 

Request a Demo

NameSilo Technologies Corp. Announces Q2 2026 Results

NEWS PROVIDED BY

NameSilo Technologies Corp.

Aug 31, 2026, 07:00 ET

SHARE THIS ARTICLE

CSE: URL / OTC: URLOF

Record Quarterly Revenues and Record Bookings

VANCOUVER, BC, Aug. 31, 2026 /PRNewswire/ -- NameSilo Technologies Corp. (CSE: URL) (PINKSHEETS: URLOF) (the "Company"), one of the largest domain registrars in the world, is pleased to announce the financial results for the quarter ending June 30, 2026. The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR+ at www.sedarplus.ca.

Q2 2026 Financial and Operating Highlights

NameSilo

The Company delivered another quarter of record financial performance, highlighted by strong growth in revenues, gross profit and total bookings. The Company also continued to invest internally generated capital into its core domain business and its newer operating subsidiaries, Reach Systems and SewerVue Technologies.

The Company's financial results for fiscal Q2 2026 are set forth below (all figures in Canadian dollars):

Record revenues of $18,803,134, compared with $16,131,881 in Q2 2025, an increase of 16.6%. Revenue growth was driven by an increase in domains under management, marketplace revenues, ancillary services and contributions from SewerVue Technologies and Reach Systems.

Gross profit of $5,350,193, or 28.5% of revenues, compared with $4,122,496, or 25.6% of revenues, in Q2 2025.

Operating income of $1,808,506, compared with $1,866,730 in Q2 2025.

Net income of $1,435,712, compared with net income of $1,170,255 in Q2 2025.

Adjusted EBITDA* of $1,550,280, compared with $1,473,241 in Q2 2025.

Record total bookings of $22,632,195*, compared with $16,084,826 in Q2 2025, an increase of 40.7%.

Total deferred revenues of $38,037,802 as of June 30, 2026, compared with $34,739,635 as of March 31, 2026.

Cash and cash equivalents of $2,243,779.

Investments, convertible loans and digital currency totaling $5,817,154.

Investing for Growth

During 2026, the Company has increased investment in personnel, product development, sales infrastructure and other growth initiatives across its operating businesses, including Reach Systems and SewerVue Technologies. While certain expenditures are expected to impact near-term profitability, management believes a meaningful portion of these investments represent one-time or non-recurring costs designed to support future growth.

The Company is beginning to see encouraging results from these investments. Reach Systems has successfully sold key products into the growing unmanned surface vehicle ("USV") market, creating a new opportunity for its specialized marine camera, tether and cable management technologies.

SewerVue Technologies has secured a growing number of pilot projects with new partners in new markets for its critical infrastructure and pipe inspection technologies. These projects provide opportunities to demonstrate SewerVue's capabilities and potentially develop broader commercial relationships in new markets.

Management believes both businesses remain in the early stages of realizing their potential and intends to continue investing in opportunities that can accelerate their growth.

Capital Allocation and Portfolio Development

The Company continues to deploy internally generated capital across a range of opportunities, including organic growth initiatives, acquisitions, strategic investments and share repurchases.

NameSilo's core domain registration business continues to grow, while the Company is investing to expand Reach Systems and SewerVue Technologies. Alchemy Labs has also successfully completed its public listing, while Ola Media is expected to pursue a public listing in the near future.

The Company continues to evaluate additional acquisition and investment opportunities where management believes capital can be deployed at attractive prospective rates of return.

Management Commentary

"We continue to be extremely pleased with the ongoing growth and momentum across our operating businesses," commented Paul Andreola, CEO of NameSilo Technologies. "Q2 was another record quarter, with revenues increasing 16.6% and total bookings increasing 40.7% year-over-year to a record $22.6 million.

"2026 is a year of investment for NameSilo. We are using the cash generated by our core business to invest in opportunities that we believe can create significantly greater value over the long term. Importantly, we are beginning to see those investments bear fruit. Reach is gaining exposure to the rapidly growing USV market, while SewerVue is securing a growing number of pilot projects with new partners in new markets.

Our core domain business continues to grow, Alchemy Labs has successfully completed its public listing, and we continue to see opportunities to grow Reach and SewerVue while evaluating additional acquisitions and investments.

Our strategy remains straightforward: grow our businesses, generate cash and intelligently redeploy that capital into opportunities where we believe we can earn attractive returns for shareholders. This includes investing in our existing businesses, pursuing acquisitions and strategic investments, and repurchasing NameSilo shares when we believe they represent compelling value.

We believe NameSilo Technologies has never been better positioned to execute this strategy, and we would like to thank all of our employees, customers and shareholders for their continued support and hard work."

www.brisio.com

www.namesilo.com

About NameSilo Technologies Corp. and NameSilo LLC

NameSilo Technologies Corp. invests its capital in companies and opportunities which management believes are undervalued and have potential for significant appreciation. The company makes investments in both public and private markets and focuses on opportunities in a wide variety of industries excluding the resource and resource service sectors. NameSilo does not invest on behalf of any third-party and it does not offer investment advice.

NameSilo LLC is a low-cost provider of domain name registration and management services. As an accredited ICANN registrar, NameSilo is one of the fastest growing domain registrars in the world with approximately 6.2 million active domains under management from approximately 160 countries.

About SewerVue Technologies

SewerVUE Technologies, has pioneered large-diameter pipe inspection technology with innovations such as pipe-penetrating radar and multisensor inspections to ensure their partners and clients have reliable, comprehensive data to make proper and well-informed decisions when it comes to maintaining critical infrastructure. Using multi-sensor tools such as LiDAR, sonar, HD-CCTV and pipe-penetrating radar, SewerVUE provides high-quality data to help customers assess and maintain critical infrastructure.

About Reach Systems

Reach Systems, based in Nanaimo, British Columbia, is an engineering and manufacturing company specializing in remote inspection robotics, subsea camera systems, and advanced tether/cable management solutions. They provide turnkey, high-definition inspection equipment for oil & gas, defense, and subsea industries, including the "Puffin" 4K underwater camera and specialized winches.

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which reflect the expectations of management regarding potential future investments by the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause the Company's actual results to differ materially from those expressed or implied by the forward-looking statements.

*Non-IFRS Financial Measure

Readers are cautioned that "Adjusted EBITDA" and "total bookings" are measures not recognized under IFRS. Adjusted EBITDA is defined as earnings before interest income, taxes, depreciation and amortization, share-based compensation, restructuring costs, impairment charges and other non-recurring gains or losses. Management believes Adjusted EBITDA is a useful measure that facilitates period-to-period operating comparisons.  Total bookings includes the full amount of cash received from new domain bookings, renewals and other related services.  Whereas, under IFRS, the Company records revenue from domain booking and renewal fees on a straight-line basis over the life of the contract term.  However, the Company's management believes that "total bookings" provides investors with insight into management's decision-making process because management uses this measure to run the business and make financial, strategic and operating decisions.  Further, "total bookings" also provides useful insight into the Company's operating performance on a yearly basis. "Total bookings" do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Readers are cautioned that "Adjusted EBITDA" and "total bookings" are not an alternative to measures determined in accordance with IFRS and should not, on their own, be construed as indicators of performance, cash flow or profitability.

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDERS (AS THAT TERM IS DEFINED IN THE POLICIES OF THE CSE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE NameSilo Technologies Corp.

21%

more press release views with 

Request a Demo

Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity

NEWS PROVIDED BY

Labcorp

Aug 31, 2026, 07:00 ET

SHARE THIS ARTICLE

Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making

BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplifying workflows and helping sponsors and investigator sites make faster, more informed decisions.

Labcorp Global Trial Connect

"As clinical trials become increasingly complex, sponsors and investigator sites need technology that helps them work more effectively," said Brian Caveney, M.D., EVP and president, Biopharma Laboratory Services and chief medical and scientific officer, Labcorp. "The latest enhancements to Global Trial Connect make it easier to access insights, manage study activities and navigate trial complexity with confidence, allowing customers to focus less on operational tasks and more on advancing research and supporting patients."

Designed with Customers, for Customers

Guided by input from more than 80 sponsors and 100 investigator sites worldwide, the latest enhancements to Global Trial Connect were informed by extensive customer feedback, product testing and direct input. Key updates include:

A more intuitive user experience with simplified navigation and role-based customization

Streamlined study management with integrated tools for study oversight, reporting and supply tracking

Embedded in-portal kit ordering that reduces manual data entry by 75% while optimizing inventory oversight and management

Greater visibility into study performance through a unified Study Oversight Dashboard that brings together study, site, sample and supply insights in a single view

Simplified report creation with a new Report Wizard that guides users through building and customizing reports to meet their needs

Enhanced sample visibility through end-to-end tracking across the sample lifecycle

Advancing the Future of Clinical Trial Delivery

These enhancements represent the latest milestone in Labcorp's ongoing investment in digital solutions across its Biopharma Laboratory Services business, helping sponsors and investigator sites deliver high-quality clinical trials more efficiently. Through continued collaboration with customers, Labcorp will further evolve Global Trial Connect to address emerging industry challenges and provide a more connected experience across the clinical trial lifecycle.

To learn more about the latest capabilities and watch an overview video of the enhancements, visit the Global Trial Connect page https://www.labcorp.com/biopharma/central-labs/global-trial-connect.

About Labcorp 

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. 

SOURCE Labcorp

21%

more press release views with 

Request a Demo

SWI devient un NVIDIA Cloud Partner (NCP) USA - Français

NEWS PROVIDED BY

SWI Group

Aug 31, 2026, 06:40 ET

SHARE THIS ARTICLE

AMSTERDAM, 31 août 2026 /PRNewswire/ -- SWI Group (AMS: SWICH), une société d'investissement disposant d'une capacité électrique de 3,6 gigawatts en Europe et aux États-Unis, a annoncé qu'il avait rejoint le programme NVIDIA Cloud Partner (NCP) en tant que partenaire privilégié.

SWI Group rejoint un cercle restreint de partenaires NVIDIA disposant de compétences validées et d'une expertise avérée en matière d'infrastructure d'IA. L'adhésion au réseau de partenaires NVIDIA permet à SWI Group d'accéder aux architectures de référence et aux configurations validées par NVIDIA, ce qui facilite le déploiement de nouvelles capacités certifiées NVIDIA à mesure que la plateforme se développe.

En tant que partenaire privilégié, SWI Group est en mesure de déployer une infrastructure informatique accélérée par NVIDIA pour une gamme complète de charges de travail d'IA, allant de l'entraînement et de l'affinage des modèles à l'inférence à l'échelle de la production et à l'IA agentique. Les compétences certifiées NVIDIA de SWI couvrent les domaines du calcul, des réseaux et des logiciels d'entreprise. Ensemble, ces éléments témoignent de l'ambition de l'entreprise de se positionner comme un fournisseur de services de calcul verticalement intégré : en déployant les derniers GPU NVIDIA dans ses propres usines d'IA et en exploitant une plateforme cloud d'IA sur le logiciel NVIDIA AI Enterprise.

« SWI Group franchit une nouvelle étape dans son parcours pour devenir un acteur mondial de l'IA pleinement intégré verticalement : au début, il y avait le foncier, l'énergie, le bâti ; aujourd'hui, ce sont les puces, les jetons et les applications. Notre collaboration avec NVIDIA nous aidera à nous forger une position solide en Europe, aux États-Unis et au-delà. », a déclaré Max-Hervé George, fondateur et PDG de SWI Group.

SWI a également acquis récemment une participation majoritaire dans Genesis Digital Assets (désormais connue sous le nom de SWI Digital), une société exploitant un centre de données d'une puissance de 1,3 GW, qui constitue son principal point d'ancrage aux États-Unis. En Europe, SWI a développé AiOnX, un portefeuille de 2,3 GW réparti entre l'Irlande, le Royaume-Uni, l'Espagne, le Danemark et l'Italie, dont un site a été loué à un hyperscaler.

Les investissements dans d'autres secteurs d'activité de SWI Group se poursuivront. Il a d'ailleurs récemment été annoncé que Varia US, géré par SWI, avait conclu un accord de coentreprise d'un montant de 693,9 millions de dollars avec Brookfield Asset Management.

À propos de SWI Group

SWI Group (SWI Capital Holding Ltd) est un groupe d'investissement international spécialisé dans les marchés privés, coté sur Euronext Amsterdam sous le mnémo SWICH. Né de la fusion entre Icona et Stoneweg, le groupe investit ses propres capitaux dans les infrastructures numériques, l'immobilier et d'autres opportunités du marché privé, alliant une approche entrepreneuriale à une discipline institutionnelle. Pour plus d'informations, rendez-vous sur www.swi.com.

21%

more press release views with 

Request a Demo

TCL Powers the Tides of Annihilation Experience at Gamescom 2026 with Advanced Display Technology

NEWS PROVIDED BY

TCL

Aug 31, 2026, 06:40 ET

SHARE THIS ARTICLE

COLOGNE, Germany, Aug. 31, 2026 /PRNewswire/ -- TCL, a leading consumer electronics brand, announced its role as the 2026 European Monitor & TV Partner of Tides of Annihilation, the upcoming fantasy action-adventure game from Eclipse Glow Games.

At gamescom 2026, TCL powers the game's public demo area in Hall 6, Booth B-050, where players can experience its dynamic lighting, cinematic environments and fast-paced combat across TCL 32X3A OLED+ Monitors and 75-inch TCL C8L SQD-Mini LED TVs.

TCL Named 2026 European Monitor & TV Partner of Tides of Annihilation

TCL 32X3A OLED+ Monitor

Developed by Eclipse Glow Games, Tides of Annihilation is a single-player adventure inspired by Arthurian legend. Set in a modern London invaded by another realm, the game follows survivor Gwendolyn through fantasy landscapes.

Stefan Streit, CMO at TCL Europe, said: "Today's gamers expect zero lag, flawless fluidity, and vivid visual fidelity that fully immerses them in new worlds. Display technology has to keep up. Through our collaboration with Tides of Annihilation, we're showing how TCL's advanced TV and monitor line-up meets extreme demands and elevates the gameplay experience for audiences across Europe."

Bringing A Visually Ambitious World to Life

High-contrast environments and dynamic lighting require displays capable of preserving detail across highlights and shadows. Fast combat and rapid camera movement also benefit from high refresh rates, fast response times and VRR support.

Through OLED+, SQD-Mini LED and high-refresh-rate technologies, TCL will demonstrate how display performance can support both cinematic presentation and responsive gameplay.

The All-Round Master: TCL 32X3A OLED+ Monitor

At the centre of the demo area is the TCL 32X3A, TCL's first flagship OLED+ monitor and winner of the 2026 iF Design Award and Red Dot Design Award.

Designed to make gameplay feel smoother, sharper and more responsive, the TCL 32X3A lets players switch between ultra-detailed visuals and high-speed performance depending on how they play. Its 480Hz dual-mode ultra-high refresh rates (UHD 240Hz / FHD 480Hz) with a 0.03ms GtG response time enable seamless switching between high resolution and high refresh performance.

OLED+ technology enhances depth and contrast so dark scenes feel richer and bright effects stand out without losing detail. Fine textures and edges remain crisp, even during intense combat or rapid movement, while the display is designed to stay clear in changing lighting conditions.

A near-borderless design helps draw players deeper into the game world, reducing distractions at the edges of the screen. Built‑in audio by Bang & Olufsen delivers clear sound to hear key in‑game moments without external speakers.

Large-screen immersion with the TCL C8L SQD-Mini LED TV

The TCL C8L SQD-Mini LED TVs bring Tides of Annihilation to life on a bigger scale, showcasing what next-generation Mini LED technology can deliver in gaming.

With up to HDR 5,500 nits peak brightness and 2,584 precise dimming zones, the C8L keeps every scene clear and balanced. A native 144Hz refresh rate with VRR support helps gameplay feel smooth and responsive, even during fast combat and quick camera shifts. Meanwhile, Audio by Bang & Olufsen with Dolby Atmos adds immersive sound that pulls players deeper into the action.

Bringing Display Innovation to the Future of Gaming

The partnership with Tides of Annihilation underscores TCL's commitment to the gaming ecosystem, aligning cutting-edge technology with the evolving expectations of players, creators and audiences across Europe.

From gaming to everyday entertainment, TCL will continue to advance its display technology and product portfolio, bringing audiences more immersive viewing experiences.

About TCL  

TCL Electronics specializes in the research, development and manufacturing of consumer electronics including TVs, mobile devices, audio devices, smart home products and appliances. Combining thoughtful design and innovative technology to inspire greatness, our lineup delivers must-have features and meaningful experiences. As one of the world's largest consumer electronics brands, our vertically integrated supply chain, and state-of-the-art display panel factory help TCL deliver innovation for all. For more information, please visit: https://www.tcl.com  

TCL is a registered trademark of TCL Corporation. All other trademarks are the property of their respective owners. 

About TIDES OF ANNIHILATION

London lies in ruin, torn apart by a cataclysmic "Outworld Invasion." Fuelled by fierce personal vengeance and a desperate mission to save her sister, Gwendolyn embarks on a high-stakes journey across two worlds: the devastated, fog-shrouded modern metropolis and the mythical realm of Avalon. Her quest through iconic landmarks, now twisted, is to unravel the mystery behind her newfound powers and ultimately determine the fate of reality itself.

About ECLIPSE GLOW GAMES

Eclipse Glow Games, a developer and publisher of PC and next generation console titles for a global audience, is located in Chengdu, Sichuan. The studio is currently developing Tides of Annihilation, an action-adventure title for PC and console based on Arthurian mythology. The Eclipse Glow team is composed of over 150 developers with previous experience creating games for storied franchises, including Yakuza, For Honor, Assassin's Creed, Persona, and Prince of Persia.

21%

more press release views with 

Request a Demo

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

NEWS PROVIDED BY

Eli Lilly and Company

Aug 31, 2026, 06:45 ET

SHARE THIS ARTICLE

Eli Lilly and Company

Merida Biosciences

Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function

Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile

Acquisition strengthens Lilly's immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need 

INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. (Merida), a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, today announced a definitive agreement for Lilly to acquire Merida.

Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The precision degradation approach is intended to address the biological cause of these diseases, rather than broadly suppressing the immune system, as many current therapies do.

Merida's lead program, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED), conditions driven by thyroid-stimulating immunoglobulins, which are autoantibodies that activate the thyroid-stimulating hormone receptor. Graves' disease affects approximately 3 million people in the U.S., and patients face elevated cardiovascular risk and mortality. Roughly 25 to 40 percent of people with Graves' disease go on to develop TED, which can cause pain, disfigurement, and in severe cases, vision loss. While there are approved treatments for both conditions, none directly target the autoantibodies that cause them. Because pathogenic autoantibodies drive a wide range of serious diseases, Merida's platform has potential application well beyond its lead program. The company's pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases driven by the antibody responsible for triggering allergic reactions, along with earlier-stage programs in kidney diseases such as membranous nephropathy and other immune-mediated conditions.

"We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects. Merida's lead program is designed to do exactly that: selectively and directly eliminating the autoantibodies causing Graves' disease and thyroid eye disease, while preserving normal immune function, with initial Phase 1 data already pointing to the potential for improved efficacy and safety," said Francisco Ramírez-Valle, M.D., Ph.D., senior vice president, Lilly immunology research and early clinical development. "We see potential to apply this precision approach across a broad range of antibody-driven diseases, and we look forward to advancing this novel technology working with the Merida team." 

"Merida was founded to fundamentally change how autoimmune and allergic diseases are treated, by targeting the antibodies driving them directly, rather than suppressing the immune system broadly. Under our CSO and founder Dario Gutierrez's scientific leadership, our team has advanced that idea from concept to clinical data, and what we've seen so far reinforces our conviction that this approach can make a meaningful difference for patients," said Adam Townsend, chief executive officer of Merida. "Today's announcement reflects the hard work of the entire Merida team, and joining Lilly gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."

Under the terms of the agreement, Lilly will acquire Merida and pay up to $2.875 billion in cash, inclusive of an upfront payment, and contingent milestone payments.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

Ropes & Gray LLP is acting as legal counsel to Lilly. Centerview Partners LLC is acting as an exclusive financial advisor, and Goodwin Procter LLP is acting as legal counsel to Merida.

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

About Merida Biosciences

Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today. Please visit www.meridabio.com to learn more.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Merida and Merida's product candidates for immune-mediated diseases, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in closing and implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will close the transaction or realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release, or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:

Megan Talon, megan.talon@lilly.com (Media)

Michael Czapar, czapar_michael_c@lilly.com (Investors)

Cynthia Clayton, cynthia@claytonbiocomms.com (Merida Media)

SOURCE Eli Lilly and Company

21%

more press release views with 

Request a Demo

Pye-Barker Fire & Safety Acquires Suppression Systems, Inc., Enhancing Fire Suppression Services in Pacific Northwest

NEWS PROVIDED BY

Pye-Barker Fire & Safety

Aug 31, 2026, 06:55 ET

SHARE THIS ARTICLE

ATLANTA, Aug. 31, 2026 /PRNewswire/ -- Pye-Barker Fire & Safety — the largest fully integrated and full-service fire protection, life safety and security services provider in the United States — has acquired Suppression Systems, Inc., a Washington-based fire suppression company. This acquisition builds on Pye-Barker's recent expansion in the region, enhancing its integrated fire protection services.

Suppression Systems, Inc., established in 1976, has offices in Tacoma, Washington, and Portland, Oregon. Its team distributes, designs, engineers and installs fire alarm, detection and suppression systems for customers throughout the Pacific Northwest.

Serving industrial, commercial, marine and high-end residential properties, Suppression Systems, Inc., has built its reputation on technically demanding projects, such as data centers, power plants and hospitals.

"There is no better way to build on our 50-year history of protecting people and property than joining Pye-Barker. Together, we will continue our legacy as the premier fire suppression partner of mission critical companies," said Zachary Tuck, owner of Suppression Systems.

"The Suppression Systems team has been a leader in special hazard fire protection systems for five decades," said Bart Proctor, CEO of Pye-Barker Fire & Safety. "Integrating their expertise and service into the Pye-Barker family provides the opportunity to achieve our shared mission of protecting more people throughout the Pacific Northwest." 

Suppression Systems, Inc.'s skilled technicians will continue to serve customers in the Pacific Northwest. Nelson Mullins Riley & Scarborough, LLP represented Pye-Barker.

About Pye-Barker Fire & Safety

As the U.S. leader in fully integrated life safety systems, Pye-Barker Fire & Safety provides complete fire protection and security systems nationwide. With over 250 locations and 9,000 team members, Pye-Barker is Great Place to Work® Certified™ and is also listed on the Inc. 5000 and ranks No. 3 on the SDM 100.

Visit pyebarkerfs.com/acquisitions to learn why we're the industry's acquirer of choice.

Contact:

Chris Jensen

VP, Business Development – M&A

chris.jensen@pyebarkerfs.com    

Media Contact:

James Taylor

jtaylor@fulltiltconsulting.com 

SOURCE Pye-Barker Fire & Safety

21%

more press release views with 

Request a Demo